Gender Disparities in the Treatment and Control of Cardiovascular Risk Factors in Type 2 Diabetes

Financial Disclosure: Dr. Berthold has no conflicts of interest to declare. Dr. Gouni-Berthold has received honoraria for speaking engagements from Pfizer and Eli Lilly. Dr. Böhm has received speakers’ honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD Sharp & Dohme, Essex Pharma, Pfizer, Servier and Sanofi-Aventis. He has been on an advisory panel for AstraZeneca, Boehringer Ingelheim, MSD Sharp & Dohme, Essex Pharma, Pfizer, Servier und Sanofi-Aventis. Dr. Mantzoros has no conflict of interest to declare. Dr. Krone has received grant/research support from MSD Sharp & Dohme and speakers’ honoraria from AstraZeneca, MSD Sharp & Dohme, Essex Pharma, Pfizer and Sanofi-Aventis. He has been on an advisory panel for MSD Sharp & Dohme and Essex Pharma. Role of the Sponsor: Employees of the Sponsor contributed to the design of the registry. The three primary authors had no participation in the planning or conduct of the study. After the study had been concluded, they had full access to all of the data. Neither the sponsor nor the CRO had a role in the evaluation and interpretation of the data or in writing the manuscript